Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 5/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16380741 | 0.81 | NOTUM (0.44) | HDAC3HDAC1HDAC2HDAC6NOTUM | |
| SCHEMBL26685531 | 0.78 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC6TACR1 | |
| SCHEMBL27075244 | 0.76 | PDE2A (0.54) | HDAC3HDAC1HDAC2HDAC6PDE2A | |
| SCHEMBL20570812 | 0.75 | AKR1C1 (0.46) | HDAC3HDAC1HDAC2HDAC6NOTUM | |
| SCHEMBL19282949 | 0.73 | PDE2A (0.51) | HDAC3HDAC1HDAC2HDAC6PDE2A | |
| SCHEMBL12513369 | 0.73 | MAPT (0.53) | HDAC3HDAC1HDAC2HDAC6PDE2A | |
| SCHEMBL22497923 | 0.73 | NOTUM (0.40) | HDAC3HDAC1HDAC2HDAC6NOTUM | |
| SCHEMBL23653998 | 0.72 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC6TAS2R14 | |
| SCHEMBL25310148 | 0.72 | SCN9A (0.53) | HDAC3HDAC1HDAC2HDAC6PDE2A | |
| SCHEMBL2030447 | 0.72 | NPSR1 (0.44) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013797-B1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-01-03 | — | — | EP | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2016-06-09 | — | — | US | disclosed |
| EP-3013797-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014206344-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BRAF, EGFR, ERBB2 | HDAC3 259/4885HDAC1 375/4885HDAC2 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.